Clearpoint Neuro Inc (CLPT)vsMerck & Company Inc (MRK)
CLPT
Clearpoint Neuro Inc
$12.89
-9.99%
HEALTHCARE · Cap: $429.45M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 161834% more annual revenue ($65.77B vs $40.61M). MRK leads profitability with a 13.6% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. MRK earns a higher WallStSmart Score of 50/100 (D+).
CLPT
Hold37
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.6%
Fair Value
$14.96
Current Price
$12.89
$2.07 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.9% year-over-year
Growing faster than its price suggests
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 20.5x book value
ROE of -154.3% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CLPT
The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CLPT
The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CLPT profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CLPT carries more volatility with a beta of 1.31 — expect wider price swings.
CLPT is growing revenue faster at 42.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?